4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q1 EPS of ($0.86), in-line with the analyst estimate of ($0.86). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $529.67 thousand.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.